Document Detail


Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
MedLine Citation:
PMID:  11812067     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Enoxaparin treatment is associated with a 20% reduction in clinical events during the acute phase of management of patients with unstable angina/non ST elevation myocardial infarction. Interest in the use of enoxaparin would be enhanced further if evidence of a durable treatment benefit over the long term could be provided. METHODS: Event rates at 1 year for the composite end-point of death/non-fatal myocardial infarction/urgent revascularization and its individual components were ascertained from the TIMI 11B and ESSENCE databases. RESULTS: There was no evidence of heterogeneity between TIMI 11B and ESSENCE in tests for interactions between treatment and trial. A significant treatment benefit of enoxaparin on the rate of death/non-fatal myocardial infarction/urgent revascularization was observed at 1 year (hazard ratio 0.88;P=0.008). The event rate was 25.8% in the unfractionated heparin group and 23.3% in the enoxaparin group, an absolute difference of 2.5%. A progressively greater treatment benefit of enoxaparin was observed as the level of patient risk at baseline increased. Treatment effects for the individual end-point elements ranged from 9-14%, favouring enoxaparin. CONCLUSIONS: The stable absolute difference in event rates of 2.5% seen at 8 days and again at 1 year favouring enoxaparin may be due to more effective control of the thrombotic process surrounding the index event. Once the pharmacological effect of enoxaparin had dissipated there was no rebound increase in events. Thus, those patients who had received enoxaparin acutely were protected from experiencing a deterioration of the original therapeutic benefit. These findings regarding enoxaparin add to the data to be considered by clinicians when selecting an antithrombin for the acute phase of management of unstable angina/non-ST elevation myocardial infarction.
Authors:
E M Antman; M Cohen; C McCabe; S G Goodman; S A Murphy; E Braunwald;
Related Documents :
12105157 - Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute c...
20492467 - Prasugrel vs. clopidogrel for cytochrome p450 2c19-genotyped subgroups: integration of...
15199477 - The present and future of heparin, low molecular weight heparins, pentasaccharide, and ...
1987387 - Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.
17174627 - Pacing evaluation-atrial support study in cardiac resynchronization therapy (pegasus cr...
6805287 - The significance of nitroglycerin-induced changes in ventricular function after acute m...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  23     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-01-28     Completed Date:  2002-03-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  308-14     Citation Subset:  IM    
Copyright Information:
Copyright 2001 The European Society of Cardiology.
Affiliation:
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angina, Unstable / drug therapy*
Enoxaparin / therapeutic use*
Fibrinolytic Agents / therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Myocardial Infarction / drug therapy*,  prevention & control
Myocardial Revascularization
Statistics as Topic
Time Factors
Chemical
Reg. No./Substance:
0/Enoxaparin; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight
Comments/Corrections
Comment In:
Eur Heart J. 2002 Feb;23(4):264-8   [PMID:  11812059 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary event...
Next Document:  Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression...